NSE - Free Realtime Quote INR

Sakar Healthcare Limited (SAKAR.NS)

Compare
291.75
-2.80
(-0.95%)
As of 10:46:17 AM GMT+5:30. Market Open.
Loading Chart for SAKAR.NS
DELL
  • Previous Close 294.55
  • Open 293.70
  • Bid 291.10 x --
  • Ask 291.65 x --
  • Day's Range 288.45 - 296.05
  • 52 Week Range 279.85 - 479.00
  • Volume 10,149
  • Avg. Volume 33,277
  • Market Cap (intraday) 6.346B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 49.03
  • EPS (TTM) 5.95
  • Earnings Date Feb 8, 2025 - Feb 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

www.sakarhealthcare.com

325

Full Time Employees

March 31

Fiscal Year Ends

Recent News: SAKAR.NS

View More

Performance Overview: SAKAR.NS

Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

SAKAR.NS
1.59%
S&P BSE SENSEX
1.66%

1-Year Return

SAKAR.NS
28.94%
S&P BSE SENSEX
6.04%

3-Year Return

SAKAR.NS
80.99%
S&P BSE SENSEX
25.84%

5-Year Return

SAKAR.NS
339.05%
S&P BSE SENSEX
84.97%

Compare To: SAKAR.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SAKAR.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    6.41B

  • Enterprise Value

    7.14B

  • Trailing P/E

    49.45

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.90

  • Price/Book (mrq)

    2.38

  • Enterprise Value/Revenue

    4.35

  • Enterprise Value/EBITDA

    16.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.52%

  • Return on Assets (ttm)

    3.90%

  • Return on Equity (ttm)

    4.90%

  • Revenue (ttm)

    1.65B

  • Net Income Avi to Common (ttm)

    124.03M

  • Diluted EPS (ttm)

    5.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.27M

  • Total Debt/Equity (mrq)

    31.13%

  • Levered Free Cash Flow (ttm)

    -418.3M

Research Analysis: SAKAR.NS

View More

People Also Watch